Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022

Rhea-AI Summary

Corvus Pharmaceuticals (CRVS) will host a conference call and webcast on November 3, 2022, at 4:30 pm ET to report its third-quarter 2022 financial results and provide a business update. Interested participants can join the call by dialing specific numbers, and a replay will be available on the company's website for 90 days. Corvus focuses on developing innovative therapies, with its lead candidate CPI-818 undergoing clinical trials for T-cell lymphomas. Other programs include CPI-444 and CPI-006, targeting critical pathways in cancer treatment.

Positive

• Upcoming conference call presents an opportunity for investors to gain insights on third-quarter financial results and business updates.

Negative

• None.

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

BURLINGAME, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on November 3, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2022 financial results.

The conference call can be accessed by dialing 1-844-825-9789 (toll-free domestic) or 1-412-317-5180 (international) and using the conference ID 10170960. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is CPI-818, an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. The Company’s second clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. Its third clinical program, mupadolimab (CPI-006), is a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical and clinical studies. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Aulani Capuchin
Real Chemistry
+1-559-355-2673
acapuchin@realchemistry.com

FAQ

What is the date of Corvus Pharmaceuticals' upcoming financial results conference call?

The conference call is scheduled for November 3, 2022, at 4:30 pm ET.

How can I access the webcast for Corvus Pharmaceuticals' conference call?

The webcast can be accessed via the investor relations section of Corvus Pharmaceuticals' website.

What are the lead product candidates of Corvus Pharmaceuticals?

Corvus' lead product candidate is CPI-818, with additional programs including CPI-444 and CPI-006.

What type of company is Corvus Pharmaceuticals?

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies.

What can investors expect from the third-quarter 2022 financial results?

Investors can expect insights into the financial performance and updates on the company's clinical programs during the conference call.